moleculin biotech, INC. (NASDAQ:MBRX) Files An 8-K Other Events
Item 8.01 Other Events.

On October 15, 2018, Moleculin Biotech, Inc. (the “Company”), to the requirements of a registration rights agreement, dated as of October 4, 2018, with Lincoln Park Capital Fund, LLC, filed with the Securities and Exchange Commission a Form S-1 registration statement. The prospectus which forms a part of such registration statement contains certain supplemental and revised disclosure regarding the Company’s business in the sections entitled “Prospectus Summary”. Such section is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Moleculin Biotech, Inc. Exhibit
EX-99.1 2 tv504858_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1   PROSPECTUS SUMMARY   This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus carefully,…
To view the full exhibit click here

About moleculin biotech, INC. (NASDAQ:MBRX)

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.